MCAC Finds Evidence Insufficient For Non-Union Bone Fracture Treatments
This article was originally published in The Gray Sheet
CMS' Medicare Coverage Advisory Committee has more confidence in the evidence supporting the efficacy of bone morphogenetic proteins (BMPs) than in the data on other orthobiologics for treating non-union bone fractures
You may also be interested in...
Medicare Coverage Advisory Committee panelists generally are confident in outcomes for vertebroplasty and kyphoplasty but find the absence of randomized, controlled clinical data for the procedures troubling
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.